Capricor Therapeutics (CAPR) Enterprise Value (2010 - 2026)

Capricor Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$278.6 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 92.44% year-over-year to -$278.6 million; the TTM figure through Mar 2026 stood at -$278.6 million (down 92.44% YoY), while the FY2025 annual figure was -$318.1 million, down 109.96% from the prior year.
• Enterprise Value was -$278.6 million for Q1 2026 at Capricor Therapeutics, up from -$318.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$28.5 million in Q3 2023 to a low of -$318.1 million in Q4 2025.
• Historically, Enterprise Value has averaged -$95.2 million across 5 years, with a median of -$51.4 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value soared 38.81% in 2023, then slumped 316.81% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$41.4 million in 2022, then grew by 4.67% to -$39.5 million in 2023, then slumped by 283.7% to -$151.5 million in 2024, then plunged by 109.96% to -$318.1 million in 2025, then climbed by 12.42% to -$278.6 million in 2026.
• The last three Enterprise Value figures came in at -$278.6 million (Q1 2026), -$318.1 million (Q4 2025), and -$98.6 million (Q3 2025), per Business Quant data.